FLT3 and acute myeloid leukemia: Over the last few years, multiple tyrosine kinase inhibitors (TKIs), including Midostaurin (MIDO), Sorafenib (SORA), Gilteritinib (GILT), and Quizartinib (QUIZ), have been developed to treat AML with FLT3 mutations (FLT3-mut AML), some of which are in clinical trials and MIDO and GILT have received U.S. Food and Drug Administration (FDA) approval (7, 8).